Highline Wealth Partners’s United Therapeutics UTHR Stock Holding History

Highline Wealth Partners’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$195K	Buy	360 +9	+3%	+$4.65K	0.04%	130
2026 Q2	$190K	Hold	351	–	–	0.04%	114
2026 Q1	$208K	Buy	351 +350	+35,000%	+$174K	0.05%	79
2025 Q4	$487	Hold	1	–	–	﹤0.01%	981
2025 Q3	$419	Hold	1	–	–	﹤0.01%	1010
2025 Q2	$287	Hold	1	–	–	﹤0.01%	843
2025 Q1	$308	Buy	+1	New	+$343	﹤0.01%	908

Other funds holding UTHR

AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.2B AUM 25.19% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return

Retirement Systems of Alabama Montgomery, Alabama $33.9B AUM 30.31% 1-Year Est. Return

Highline Wealth Partners's UTHR Position: Q3 2026 in Review

Highline Wealth Partners increased its United Therapeutics (UTHR) stake by 2.6% in Q3 2026, buying an estimated $4.65K and bringing the position to 360 shares worth $195K. The position accounts for 0.04% of the portfolio, ranked #130.

Highline Wealth Partners first reported a position in UTHR in Q1 2025 and has held it in 7 quarters since. The position peaked at $208K in Q1 2026. 362 funds tracked by Wall St. Rank hold UTHR as of Q3 2026.

Highline Wealth Partners held 360 shares of United Therapeutics worth $195K as of Q3 2026.
Highline Wealth Partners bought 9 United Therapeutics shares in Q3 2026, an estimated $4.65K.
United Therapeutics made up 0.04% of Highline Wealth Partners's portfolio in Q3 2026, its #130 holding.
Highline Wealth Partners first reported a position in United Therapeutics in Q1 2025 and has held it in 7 quarters since.
Highline Wealth Partners's United Therapeutics position peaked at $208K in Q1 2026.
362 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2026.

Based on Highline Wealth Partners's 13F filing for Q3 2026, filed 19 Oct 2026.